The mission of St. Jude Children's Research Hospital is to find cures for children with catastrophic illnesses through research and treatment. Founded by the late entertainer, Danny Thomas, the hospital opened in 1962. The resources of the hospital have been focused on pediatric cancer throughout its 39-year history. Supported by a CCSG for 24 years, St. Jude Children's Cancer Center is the only NCI funded Cancer Center dedicated exclusively to research and treatment of cancer in children. Mr. Thomas also founded the American Lebanese Syrian Associated Charities (ALSAC), a separate corporation whose only purpose is to raise money in support of St. Jude Children's Research Hospital. Patients are accepted without regard to race, religion or ability to pay. Any costs beyond that provided by third party payers are covered by ALSAC, allowing our research to be conceptually driven without the usual financial constraints on clinical investigation in the context of patient care. The Cancer Center is dedicated to long-term follow-up of its patients, thereby providing a framework for growing cancer prevention and control research initiatives which are encompassed within our research programs. Public support of the hospital through ALSAC provides an unusually strong foundation for our Cancer Center upon which extramurally funded research and CCSG support can be leveraged to their fullest potential. The St. Jude Children's Cancer Center has seven multidisciplinary research programs which collectively span the spectrum from discovery oriented research to clinical application with an emphasis on translation. Research by the 136 members of the Cancer Center is supported by 17 Shared Resources, three of which have been developed during the last cycle and which we are now proposing for CCSG funding. The overall structure of our Cancer Center and its leadership, enhanced by the recruitment of three additional, strong scientific leaders, has otherwise remained very stable. New or rapidly growing research initiatives include Developmental Neurobiology, Structural Biology, Bioinformatics and Biotechnology. Our extramural support for cancer research has nearly doubled from $21.3 million in 1996 to over $40 million today. Planned future initiatives include Chemical Biology and expansion of Immunology. In summary, our Cancer Center has grown substantially and been greatly strengthened during the past five years through recruitment, maturation of our programs and development of new research initiatives.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA021765-25S1
Application #
6602244
Study Section
Subcommittee G - Education (NCI)
Program Officer
Rosenfeld, Bobby
Project Start
1977-09-01
Project End
2007-02-28
Budget Start
2002-06-24
Budget End
2003-02-28
Support Year
25
Fiscal Year
2002
Total Cost
$89,800
Indirect Cost
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
Gibson, Todd M; Li, Chenghong; Armstrong, Gregory T et al. (2018) Perceptions of future health and cancer risk in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. Cancer 124:3436-3444
Yang, Kai; Blanco, Daniel Bastardo; Chen, Xiang et al. (2018) Metabolic signaling directs the reciprocal lineage decisions of ?? and ?? T cells. Sci Immunol 3:
Ferrolino, Mylene C; Mitrea, Diana M; Michael, J Robert et al. (2018) Compositional adaptability in NPM1-SURF6 scaffolding networks enabled by dynamic switching of phase separation mechanisms. Nat Commun 9:5064
Bjornard, Kari L; Gilchrist, Laura S; Inaba, Hiroto et al. (2018) Peripheral neuropathy in children and adolescents treated for cancer. Lancet Child Adolesc Health 2:744-754
Luo, Yi; Shao, Lijian; Chang, Jianhui et al. (2018) M1 and M2 macrophages differentially regulate hematopoietic stem cell self-renewal and ex vivo expansion. Blood Adv 2:859-870
Peterson, Rachel K; Ashford, Jason M; Scott, Sarah M et al. (2018) Predicting parental distress among children newly diagnosed with craniopharyngioma. Pediatr Blood Cancer 65:e27287
Kumar, Rahul; Liu, Anthony P Y; Orr, Brent A et al. (2018) Advances in the classification of pediatric brain tumors through DNA methylation profiling: From research tool to frontline diagnostic. Cancer 124:4168-4180
Rusch, Michael; Nakitandwe, Joy; Shurtleff, Sheila et al. (2018) Clinical cancer genomic profiling by three-platform sequencing of whole genome, whole exome and transcriptome. Nat Commun 9:3962
Kurmasheva, Raushan T; Kurmashev, Dias; Reynolds, C Patrick et al. (2018) Initial testing (stage 1) of M6620 (formerly VX-970), a novel ATR inhibitor, alone and combined with cisplatin and melphalan, by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 65:
Chamdine, Omar; Elhawary, Ghada Ahmad Saad; Alfaar, Ahmad Samir et al. (2018) The incidence of brainstem primitive neuroectodermal tumors of childhood based on SEER data. Childs Nerv Syst 34:431-439

Showing the most recent 10 out of 6764 publications